(Q37161653)

18 August 2017

1 reference

title

Immunobiology of HPV and HPV vaccines (English)

1 reference

18 August 2017

1

Margaret Stanley

1 reference

PubMed ID

18474288

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

109

1 reference

18 August 2017

S15-21

1 reference

18 August 2017

2 Suppl

1 reference

Papillomaviruses and cancer: from basic studies to clinical application

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Classification of papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

The papillomavirus life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Mechanisms of human papillomavirus-induced oncogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Immune responses to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Links between innate and adaptive immunity via type I interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Mechanisms used by human papillomaviruses to escape the host immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Immunological events in regressing genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

The serological response to papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

IMMUNIZATION OF RABBITS TO INFECTIOUS PAPILLOMATOSIS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Chapter 13: Current findings from prophylactic HPV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2008.02.003

1 reference

18 August 2017

1 reference

PubMed ID

18474288